Publications in collaboration with researchers from Essen University Hospital (20)

2025

  1. Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

    Future Oncology, Vol. 21, Núm. 9, pp. 1033-1044

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

  2. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review

    JAMA Oncology, Vol. 8, Núm. 12, pp. 1830-1839

2019

  1. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

    Lung Cancer, Vol. 132, pp. 126-131

2018

  1. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479

2017

  1. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

2015

  1. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588

  2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135

2014

  1. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484

  2. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474

  3. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

    Clinical Cancer Research, Vol. 20, Núm. 16, pp. 4251-4261

  4. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

    Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690

2013

  1. Epidermal growth factor receptor inhibition in lung cancer: Status 2012

    Journal of Thoracic Oncology, Vol. 8, Núm. 3, pp. 373-384

  2. Strategies for improving outcomes in NSCLC: A look to the future

    Lung Cancer, Vol. 82, Núm. 3, pp. 375-382

2011

  1. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study

    The Lancet Oncology, Vol. 12, Núm. 1, pp. 30-37

  2. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

    Journal of Clinical Oncology

2008

  1. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program

    Journal of Thoracic Oncology, Vol. 3, Núm. 7, pp. 756-763